Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
Rhea-AI Summary
Oncolytics (Nasdaq: ONCY) announced FDA alignment on a pivotal, randomized controlled trial of pelareorep in unresectable metastatic squamous cell carcinoma of the anal canal (SCAC) on April 27, 2026. The trial is intended to support both accelerated and full approval within a single study framework.
Key clinical signals cited include a combination study in second-line+ SCAC showing median duration of response 15.5 months vs 9.5 months and 12-month survival 82% vs 45.7% versus current standard of care. Final protocol will incorporate FDA feedback.
Positive
- FDA alignment on a randomized pivotal SCAC trial
- Design aims to enable both accelerated and full approval
- Median duration of response 15.5 months versus 9.5 months
- 12-month survival 82% versus 45.7% in second-line+ SCAC study
Negative
- Randomized pivotal trial likely increases trial size, time, and cost
- Final protocol not yet set; regulatory and design details remain pending
News Market Reaction – ONCY
In the Apr 27 session, ONCY declined 5.95%, reflecting a notable negative market reaction. Argus tracked a peak move of +2.6% during that session. Argus tracked a trough of -22.6% from its starting point during tracking. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 5.7x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 06 | FDA meeting scheduled | Positive | -1.1% | Planned Type C FDA meeting to discuss single-arm SCAC registrational pathway. |
| Apr 01 | Redomestication | Positive | +9.6% | Completed domicile change to Nevada to streamline structure and access U.S. markets. |
| Mar 19 | AACR data update | Positive | +1.9% | New AACR 2026 mechanistic data supporting pelareorep as immune-priming backbone. |
| Mar 02 | Trial launch | Positive | -9.7% | Launch of randomized Phase 2 colorectal cancer study with pelareorep combination. |
| Feb 24 | Strategy update | Positive | +6.6% | Prioritization of registration-focused programs in SCAC and metastatic colorectal cancer. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent ONCY news has produced mixed reactions, with both strong gains and notable selloffs following positive development updates and program prioritization.
This announcement follows several months of development-focused updates. On Mar 2, 2026, Oncolytics launched a randomized colorectal cancer study, and on Feb 24, 2026 it prioritized registration-focused programs in anal and colorectal cancer. A Type C FDA meeting for a potential single‑arm SCAC pathway was disclosed on Apr 6, 2026, and the company completed its U.S. domicile change by Apr 1, 2026. The new FDA alignment on a randomized pivotal anal cancer study builds directly on these prior regulatory and strategic steps around pelareorep.
Key Terms
pivotal clinical study regulatory
randomized controlled trial medical
accelerated approval regulatory
full approval regulatory
checkpoint inhibitor medical
median duration of response medical
unresectable medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma
Pivotal study expected to focus on patients in a post-standard-of-care patient population with no FDA-approved therapies
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown to activate innate immune-sensing pathways, today announced that a Type C meeting with the U.S. Food and Drug Administration (“FDA”) has resulted in alignment on the design of a pivotal clinical study to support approval of pelareorep in patients with unresectable metastatic squamous cell carcinoma of the anal canal (“SCAC”).
“We want to thank the FDA for its very clear guidance and helping us create an efficient pathway for pelareorep in a disease that is desperate for new treatments,” said Jared Kelly, Chief Executive Officer of Oncolytics. “While a single-arm study was possible in this setting, following a productive discussion with the FDA and in consideration of recent regulatory decisions regarding similar studies, we have aligned on a randomized controlled trial designed to potentially support both accelerated approval and full approval within the same study. This approach directly addresses relevant and rigorous evidentiary standards while allowing for approval based on multiple endpoint assessments.”
SCAC is a rare gastrointestinal malignancy affecting more than 10,000 patients annually in the United States. Patients whose disease progresses following first-line chemotherapy/checkpoint inhibitor treatment have no FDA-approved therapeutic options and limited National Comprehensive Cancer Network recommended treatments. In a recent study combining pelareorep with a checkpoint inhibitor in second-line and later SCAC, the combination achieved a median duration of response of 15.5 months versus 9.5 months and 12-month survival of
“The post-first-line SCAC setting remains an area of significant unmet need,” said Dr. Van Morris, Associate Professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston, TX. “Pelareorep provides a strong rationale for evaluation in this population, and the study design represents a thoughtful and appropriate approach to advancing new options for these patients.”
The Company plans to incorporate FDA feedback into the final protocol, which is expected to be a single, randomized controlled trial for which accelerated approval and full approval could be applied at different points in time.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses.
The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on social media on LinkedIn and on X @oncolytics.
Reference
- Rao S, et al. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open. 2022 Aug;7(4):100529
Forward-looking statements
This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding beliefs as to the potential, registration, mechanism of action and benefits of pelareorep as a cancer therapeutic; the Company’s goals, strategies, and objectives; expectations around the design, milestones, anticipated timelines and expected outcomes for current and future studies, and projected outcomes of the Company’s planned clinical study of pelareorep, including the potential for accelerated regulatory approval; its belief in the clinical promise of pelareorep in anal, colorectal, pancreatic and other gastrointestinal cancers; and the Company’s goals and expectations for its potential registrational development path for pelareorep in multiple gastrointestinal cancers. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
